Premium
Clinical Considerations for Oncolytic Viral Therapies: A Regulatory Perspective
Author(s) -
Liu K
Publication year - 2017
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.640
Subject(s) - oncolytic virus , medicine , food and drug administration , viral therapy , melanoma , oncology , drug approval , drug , cancer research , covid-19 , pharmacology , cancer , disease , infectious disease (medical specialty)
The US Food and Drug Administration (FDA) approved the first oncolytic viral therapy (OVT), Imlygic (talimogene laherparepvec), in October 2015 for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery, although talimogene has not been shown to improve overall survival or have an effect on visceral metastases.[1][, 2015]